Med BioGene Inc.

Med BioGene Inc.

September 24, 2007 08:30 ET

Med BioGene Appoints Dr. Melanie M. Mahtani as Executive Advisor, Commercial Development

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 24, 2007) - Med BioGene Inc. (TSX VENTURE:MBI), a life science company focused on the development and commercialization of genomic-based diagnostic and screening tests for cancer and cardiovascular disease, is pleased to announce the appointment of Melanie M. Mahtani, Ph.D. as Executive Advisor, Commercial Development.

Dr. Mahtani brings to MBI extensive experience in molecular diagnostics and personalized medicine, including over 15 years in the development and commercialization of novel genomic and genetic tests and technology for human disease analysis and profiling. Dr. Mahtani was most recently Vice President, Corporate Business Development at Panomics where, among other things, she led the company's strategic partnering activities with major diagnostics, pharmaceutical and biotechnology companies. Dr. Mahtani was previously Director, Microarray Systems R&D at Amersham Biosciences (now GE Healthcare) where she was responsible for developing new global businesses in high throughput genomic analysis. She joins MBI as the company prepares for the partnering and commercialization of its genomic-based clinical laboratory diagnostic test for lymphoma, LymphExpress Dx™.

Dr. Mahtani received her doctorate in medical genetics from Stanford University and pioneered whole genome approaches to diabetes and other complex diseases as a postdoctoral fellow at the Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology Center for Genome Research.

Erinn B. Broshko, Chief Executive Officer of MBI, noted, "Dr. Mahtani joins the Med BioGene team at a crucial time as LymphExpress Dx™ moves toward commercialization. The company will gain significant value from Dr. Mahtani's experience in molecular diagnostics and strategic partnering and through her work with many of the key players in this rapidly evolving space. We look forward to working with her."

"Med BioGene is targeting some of the earliest opportunities in the evolving molecular diagnostics market. The Company's tests focus on diseases, including lymphoma and leukemia, where molecular diagnostics can have a dramatic impact on clinical management and tailored therapy. I look forward to helping Med BioGene achieve commercial success," noted Dr. Mahtani.

About Med BioGene

MBI is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic and screening tests for cancer and cardiovascular disease. MBI develops these tests by identifying the genes, known as "biomarkers", which indicate the presence of disease. The development of these tests is the first step towards personalized medicine and will replace the conventional "one drug fits all" approach to disease management.

Expected benefits include:

- more accurate, quicker and less invasive diagnosis;

- tailoring of treatment decisions to the needs of each patient by outlining a patient's genetic profile, thus making treatment more effective and reducing healthcare costs by minimizing the treatment of non-responders; and

- prioritizing of genomic biomarkers for use as potential therapeutic targets and to validate the effectiveness of specific therapeutics.

MBI is currently developing tests for lymphoma, leukemia and cardiovascular disease through the following products: LymphExpress Dx™, LeukExpress Dx™ and CardioExpress Dx™.

Certain statements in this press release contain forward-looking information under applicable Canadian securities legislation. Words such as "anticipates", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "will", "would" and similar expressions are intended to identify forward-looking information, although not all forward-looking information contains these identifying words. Forward looking information includes, but is not limited to, that with respect to future profits, future product revenues, future operations and plans, the use of proceeds from financings, the timing of clinical trials and the completion date for clinical trials and the prospects for negotiating partnerships or collaborations and their timing. This forward-looking information is only a prediction based upon MBI's current expectations, and actual events or results may differ materially. MBI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking information. Forward-looking information is subject to known and unknown risks and uncertainties and is based on uncertain assumptions that could cause MBI's actual results and the timing of events to differ materially from those anticipated in such forward-looking information. You are cautioned not to place undue reliance on this forward-looking information, which speaks only as of the date of this press release. MBI's forward-looking information does not reflect the potential impact of any future partnerships, collaborations, acquisitions, mergers, dispositions, joint ventures or investments that MBI may make. All forward-looking information is qualified in its entirety by this cautionary statement and MBI undertakes no obligation to revise or update any forward-looking information as a result of new information, future events or otherwise after the date of this press release, other than as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information